SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?


To: Mailbu who wrote (2089)7/22/1998 10:49:00 AM
From: Mailbu  Respond to of 4676
 
Wednesday July 22, 10:08 am Eastern Time

Isis says FDA reviewing Vitravene

NEW YORK, July 22 (Reuters) - Isis Pharmaceuticals' Vitravene blindness drug is being reviewed
by a U.S. Food and Drug Administration Advisory Committee, said Marian Chabansky, a
spokeswoman for the company, to Reuters on Wednesday.

Vitravene is used to treat retinal blindness which affects AIDS patients.

Chabansky said the company hopes the advisory committee recommends that the FDA approve
Vitravene for marketing.

Earlier on Wednesday, the Nasdaq Stock Market halted trade on Isis Pharmaceuticals stock
pending news. The stock closed on July 21 at $13.44.

More Quotes and News:
ISIS Pharmaceuticals Inc (Nasdaq:ISIP - news)
Related News Categories: health